Clinical trials: Polycystic Liver Disease
Polycystic Liver Disease, Hepatomegaly
Open-Label Extension of LOCKCYST Trial
Positive data originating from two polycystic liver patients treated with somatostatin analogues, showed a volume reduction of 38.3% and 14.9%.
- Conditions
- Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Polycystic Kidney
- Trial name
- LOCKCYST-ext (NCT00771888)
- Testing
- lanreotide
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 54 people
- Sponsor
- Radboud University Medical Center
Polycystic Ovary Syndrome
Exploring Liver and Muscle Fat Content Using MRI
The aim of our study was to compare the difference of fatty infiltration in liver and muscle using magnetic resonance imaging (MRI) between overweight as well as obese polycystic ovary syndrome (PCOS) cases and body mass index…
- Trial name
- NCT05592080
- Testing
- MRI
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bing He
Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease
Octreotide in Severe Polycystic Liver Disease
This study will evaluate the effect of Octreotide LAR® on the liver volumes of patients with severe polycystic liver disease who are not candidates or decline surgical treatments such as liver cyst fenestration, liver resection…
- Conditions
- Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases
- Trial name
- NCT00426153
- Testing
- Octreotide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
PCOS, NAFLD
Androgens and NAFLD Longitudinal Cohort Study
The researchers want to learn how androgens, a type of sex hormone, might affect nonalcoholic fatty liver (NAFLD) in young women over time.
- Conditions
- PCOS, NAFLD, NASH
- Trial name
- NCT06124261
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Francisco
Obesity
Clinical Efficacy and Safety of a Laparoscopic Sleeve Gastrectomy in Obese Patients
This study aim to evaluate the clinical efficacy and safety after laparoscopic sleeve gastrectomy in patients with obesity. 300 patients with obesity and 49 healthy individuals with normal BMI were enrolled.
- Trial name
- NCT04548232
- Testing
- Laparoscopic sleeve gastrectomy
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Shanghai 10th People's Hospital
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome
The goal of this clinical trial is to investigate the use of ultra-high performance liquid chromatography-mass spectrometry for metabolomics and proteomics research in patients with Polycystic Ovary Syndrome (PCOS) and…
- Trial name
- NCT06256289
- Testing
- Canagliflozin 100mg Tab, Metformin Hydrochloride
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ping Li,MD
Polycystic Ovary Syndrome (PCOS) With Concurrent Nonalcoholic Fatty Liver Disease (NAFLD)
Evaluation of the Therapeutic Effects of Curcumin on Changes in Lipid, Metabolic, and Hormonal Profiles, Liver Enzyme Activity, and Ultrasonography Morphology of the Liver in Women With Polycystic Ovary Syndrome and Nonalcoholic Fatty Liver Disease: A Double-blind, Placebo-controlled Clinical Trial
Background and Objectives: Polycystic ovary syndrome (PCOS) and nonalcoholic fatty liver disease (NAFLD) commonly co-occur and are associated with insulin resistance, chronic inflammation, and metabolic and hormonal imbalances.
- Trial name
- NCT07278128
- Testing
- Patients (women of reproductive age suffering from non-alcoholic fatty liver with polycystic ovary syndrome) receiving 500 mg curcumin capsules (prepared from the extraction of turmeric in the laborat
- Where
- Iran
- Volunteers
- 74 people
- Sponsor
- Fateme Moshirenia
Non-alcoholic Fatty Liver Disease in Women With PCOS
Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)
This is a multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well characterized PCOS.
- Trial name
- NCT03617263
- Testing
- Saroglitazar Magnesium 4 mg Tablet
- Where
- 19 sites in United States, Mexico
- Volunteers
- 60 people
- Sponsor
- Zydus Therapeutics Inc.
Autosomal Dominant Polycystic Kidney Disease
Effects of Somatostatin on Liver in ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) is associated with the development of a variety of extrarenal manifestations of which polycystic liver disease is most common.
- Trial name
- NCT02119052
- Testing
- octeotride
- Volunteers
- 35 people
- Sponsor
- Federico II University
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Polycystic Liver Disease
Everolimus and LongActing Octreotide Trial in Polycystic Livers
The aim of this study is to reduce polycystic liver volume by treating with octreotide, whether or not combined with everolimus; to assess whether combination therapy of everolimus and octreotide gives a bigger reduction of…
- Trial name
- ELATE (NCT01157858)
- Testing
- Everolimus, Octreotide LAR
- Where
- Netherlands
- Volunteers
- 44 people
- Sponsor
- Radboud University Medical Center
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Study of Lanreotide to Treat Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation in both kidneys, in most patients leading to end stage renal disease.
- Trial name
- DIPAK1 (NCT01616927)
- Testing
- Lanreotide
- Where
- 4 sites in Netherlands
- Volunteers
- 300 people
- Sponsor
- University Medical Center Groningen
Polycystic Liver Disease, Polycystic Hepatorenal Disease
Automatic Segmentation of Polycystic Liver
Assessing the volume of the liver before surgery, predicting the volume of liver remaining after surgery, detecting primary or secondary lesions in the liver parenchyma are common applications that require optimal detection of…
- Conditions
- Polycystic Liver Disease, Polycystic Hepatorenal Disease, Liver Injury
- Trial name
- ASEPOL (NCT03960710)
- Testing
- Anonymized CT examinations, Training (1), Training (2)
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
This project, "A double-blind placebo-controlled randomized clinical trial assessing the efficacy of metformin for hepatic fat in adolescents and young adults with polycystic ovary syndrome", proposes exploring the use of novel…
- Conditions
- Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
- Trial name
- NCT02500147
- Testing
- Metformin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Columbia University
Polycystic Ovarian Syndrome, Obesity
Post-Prandial Liver Glucose Metabolism in PCOS
The Investigators will measure if hepatic metabolism is upregulated in obese girls with PCOS and hepatic steatosis (HS), compared to PCOS without HS and obese controls without HS.
- Conditions
- Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
- Trial name
- PLUM (NCT03041129)
- Testing
- oral glucose tolerance test, MRI of liver
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
NAFLD (Nonalcoholic Fatty Liver Disease), Polycystic Ovarian Syndrome (PCOS)
PolyCystic Ovary Syndrome as Suggested Risk Group for Non-Alcoholic Fatty Liver Disease
To study the prevalence, non-invasive diagnostics and evolution of non-alcoholic-fatty-liver-disease (NAFLD) in patients with polycystic ovary syndrome (PCOS)
- Trial name
- P-CORIGA (NCT07146815)
- Testing
- FibroScan, MRI PDFF
- Where
- Belgium
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Ziekenhuis Oost-Limburg
Somatostatin Analogs, Polycystic Liver Disease
Pasireotide LAR in Severe Polycystic Liver Disease
The purpose of this study is to compare SOM230 treatment to placebo. The investigators will also assess the efficacy and safety of SOM230 in reducing total liver volume and improving quality of life.
- Conditions
- Somatostatin Analogs, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney Disease, Autosomal Dominant Polycystic Liver Disease
- Trial name
- SOM230 (NCT01670110)
- Testing
- Pasireotide LAR
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Mayo Clinic
Polycystic Kidney Diseases
Sirolimus for Massive Polycystic Liver
The purpose of this study is to evaluate the effectiveness and safety of Sirolimus in reducing liver volume in autosomal dominant polycystic kidney disease.
- Trial name
- SILVER (NCT01680250)
- Testing
- Sirolimus
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Seoul National University Hospital
Autosomal Dominant Polycystic Kidney, Renal Cyst
A Prospective Observational Study of Foam Sclerotherapy .
An observational prospective study to determine the impact of foam sclerotherapy of large, dominant kidney/liver cysts on quality of life outcomes and kidney/liver cyst volumes at up to 12 months of follow-up in patients with…
- Conditions
- Autosomal Dominant Polycystic Kidney, Renal Cyst, Autosomal Dominant Polycystic Liver Disease, Hepatic Cyst
- Trial name
- NCT04111692
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Autosomal Dominant Polycystic Kidney Disease
The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients
The investigators multicenter randomized open-labelled study will investigate the efficacy of an everolimus based immunosuppression in reducing total native kidney volume in kidney recipients with autosomal dominant polycystic…
- Trial name
- EVERKYSTE (NCT02134899)
- Testing
- Everolimus, Calcineurin inhibitors maintenance
- Where
- France
- Volunteers
- 3 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris